Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A model-based analysis of the HERA and FinHer trial

Annals of Oncology

Volumn 18, Issue 9, 2007, Pages 1493-1499

  Dedes, Konstantin J ^a   Szucs, T D ^b   Imesch, P ^a   Fedier, A ^a   Fehr, M K ^a   Fink, D ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adjuvant treatment; Breast cancer; Cost effectiveness; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EARLY CANCER; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; STATISTICAL MODEL; SWITZERLAND; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MARKOV CHAINS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; VALIDATION STUDIES AS TOPIC;

EID: 34548396846     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm185     Document Type: Article

References (33)

1. Leyland-Jones B. Trastuzumab: Hopes and realites. Lancet Oncol 2002; 3: 137-144.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
4. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-329.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
6. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
8. Cox MC, Figg WD, Thurman PW. No rational theory for drug pricing. J Clin Oncol 2004; 22: 962-963.
9. Neyt M, Albrecht J, Cocquyt V. An economic evaluaton of Herceptin in adjuvant setting: The Breast Cancer International Research Group 006 trial. Ann Oncol 2006; 17: 381-390.
10. Hillner BE. Clinical and cost-effectiveness implications of the adjuvant transtuzumab in HER2+ breast cancer trials. Breast Cancer Res Treat 2005; 94 (Suppl 1): S1-S287.
11. Norum J, Olsen JA. Trastuzumab in adjuvant breast cancer therapy: A model based cost-effectiveness analysis. J Clin Oncol 2006; 24: (Abstr 628).
12. Wardley AM, Cameron DA, Bell R et al. Cost-effectiveness analysis of adjuvant therapy with trastuzumab (Herceptin) for early breast oancer. Ann Oncol 2006; 17: Ix95.
13. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-458.
14. Drummond MF, Sculpher MJ, Torrance GW et al. Methods of the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford University Press 2005.
15. Swiss Federal Office of Statistics. Mortality Rates. http://www.bfs.admin.ch (12 November 2007, date last accessed).
16. Shen J, Hunt KK, Mirza NQ et al. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer 2005; 104: 479-490.
17. Harris EE, Hwang WT, Seyednejad F, Solin LJ. Prognosis after regional lymph node recurrence in patents with stage I-II breast carcinoma treated with breast conservation therapy. Cancer 2003; 98: 2144-2151.
18. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for earty breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366: 2087-2106.
19. National Institute for Health and Clinical Excellence. http://www.nice.org.uk (12 November 2007, date last accessed).
20. Smith I, Procter M, Gelber RD et al. Improved survival with trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Lancet 2006; 369: 29-36.
21. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicily: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7826.
22. Schweizerische Arzneimittelkompendium. http://www.documed.ch (12 November 2007, date last accessed).
23. Tarmed Suisse. http://www.tarmed.org (12 November 2007, date last accessed).
24. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: A model-based cost-effectiveness analysis. Ann Oncol 2005; 16: 909-914.
25. Ess SM, Luscher TF, Szucs TD. High dose lisinopril in heart failure: economic considerations. Cardiovasc Drugs Ther 2002; 16: 365-371.
26. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N Engl J Med 2005; 353: 2747-2757.
27. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
28. Molitemi A, Menard S, Valagussa P et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 2003; 21: 458-462.
29. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National surgical adjuvant breast and bowel project protocol B-15. J Natl Cancer Inst 2000; 92: 1991-1998.
30. Eichler HG, Kong SX, Gerth WC et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-528.
31. Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-390.
32. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004; 101: 1311-1322.
33. Cameron DA, Geyer CE, Chan DS et al. Lapatinib in combination with capecitabine demonstrates superior efficacy compared with capecitabine alone in ERBB2+ advances oi metastatic breast cancer patients pretreated with chemotherapy and trastuzumab. Ann Oncol 2006; 17: Ix69.